Evercore Inc.’s (EVR) fourth-quarter 2024 adjusted earnings per share of $3.41 surpassed the Zacks Consensus Estimate of $2.90. Also, the bottom line compared favorably with the prior-year quarter’s $2.02. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Results benefited from an increase in revenues generated from the Investment Management, and Investment Banking & Equities segments.  An improvement in assets under management (AUM) balance was another positive. However, the rise in ...

Evercore Inc. (NYSE:EVR) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Company Participants Katy Haber - Managing Director, Investor Relations & ESG John Weinberg - Chairman & Chief Executive Officer Tim LaLonde - Chief Financial Officer Conference Call Participants Mike Brown - Wells Fargo Brennan Hawken - UBS Devin Ryan - Citizens JMP James Yaro - Goldman Sachs Brendan O'Brien - Wolfe Research Aidan Hall - KBW Ryan Kenny - Morgan Stanley Operator Followed by the number one on your touch ton ...

For the quarter ended December 2024, Evercore (EVR) reported revenue of $980.5 million, up 25% over the same period last year. EPS came in at $3.41, compared to $2.02 in the year-ago quarter.The reported revenue represents a surprise of +12.81% over the Zacks Consensus Estimate of $869.15 million. With the consensus EPS estimate being $2.90, the EPS surprise was +17.59%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine thei ...

Evercore (EVR) came out with quarterly earnings of $3.41 per share, beating the Zacks Consensus Estimate of $2.90 per share. This compares to earnings of $2.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 17.59%. A quarter ago, it was expected that this investment bank would post earnings of $1.95 per share when it actually produced earnings of $2.04, delivering a surprise of 4.62%.Over the last four quarters, the company h ...

| g | Fourth Quarter and Full Year Net Revenues were $975.3 million and $3.0 billion, respectively, on a U.S. | GAAP basis and $980.5 million and $3.0 billion, respectively, on an Adjusted basis, representing the second | | | | | --- | --- | --- | --- | --- | --- | | best Quarter and Full Year by both measures. Fourth Quarter and Full Year 2024 Net Revenues increased | 24% and 23%, respectively, on both a U.S. GAAP basis and an Adjusted basis versus 2023 | | | | | | g | Fourth Quarter Operating Income of $2 ...

Investment Strategy - The Value Lab focuses on long-only value ideas, targeting international mispriced equities with a portfolio yield of about 4% [1] - The Valkyrie Trading Society shares high-conviction developed market ideas that are downside limited and aim to generate non-correlated and outsized returns [3] Services Offered - The Value Lab provides members with a portfolio featuring real-time updates, 24/7 chat support, global market news reports, feedback on member stock ideas, new trades monthly, quarterly earnings write-ups, and daily macro opinions [2] Performance and Experience - The Value Lab has performed well over the last 5 years, leveraging experience in international markets [1]

SECAUCUS, N.J., Dec. 3, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 7th Annual Evercore HealthCONx Conference in Miami on Wednesday, December 4, 2024, at 3:00 p.m. Eastern Time.The fireside chat and Q&A session will be webcast live during the conference and will be ...

CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 7th Annual Evercore ISI HealthCONx Conference. Management is scheduled to participate in a fireside chat discussion on December 5, 2024, at 8:20 am ET. Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at htt ...

HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7th Annual Evercore HealthCONx Conference to be held in Coral Gables. Florida, December 3 – 5, 2024. 7th Annual Evercore HealthCONx Conference  Presentation Date:December 4, 2024  Time:7:55 ...

NESS ZIONA, Israel, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 7th Annual Evercore HealthCONx Conference, to take place December 3-5, 2024, in Coral Gables, Florida. Mapi is actively seeking new partnership opportunities for its proprietary Depot products. Company management will be available for one-on-one meetings during t ...